In addition, Lcn-2 expression was reported to be higher in progressive MS compared with RRMS, and Lcn-2 levels in the cerebrospinal fluid correlated with neurofilament light chain levels, i.e., axonal damage. This evidence concerns the gene LCN2 and myeloid sarcoma.